Global Biodesign
The computed 12-month bankruptcy probability of Global Biodesign is 0.3% (very low). The 2024 annual accounts show equity of €10k and a net result of €1k. Equity is growing by ~53.9% per year across the filed fiscal years. Its solvency ranks better than 43% of 811 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €10k |
| Net result | €1k |
| Better than sector | 43% |
| Active | 5 yrs |
Strong profile, led by stability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 14.8% | 20.3% | |
| Net result | €1k | €5k | |
| Equity | €10k | €37k | |
| Gross operating margin | €91k | €33k | |
| Staff costs | €87k | €21k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €4k |
| Net profit | €1k |
| Cash flow | €3k |
| Staff costs | €87k |
| Income taxes | €368 |
| Dividends | - |
| Total assets | €71k |
| Equity | €10k |
| Debt | €60k |
| of which ≤ 1y | €60k |
| of which > 1y | - |
| Working capital | €5k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 1.08 |
| Quick ratio | 1.08 |
| Working capital ratio | 6.9% |
| Solvency | 14.8% |
| Debt / equity | 5.76 |
| Long-term debt ratio | - |
| Interest coverage | 7.99 |
| Gross margin | - |
| Net margin | - |
| ROA | 1.4% |
| ROE | 9.6% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €71k |
| Fixed assets | 21/28 | €6k |
| Tangible fixed assets | 22/27 | €6k |
| Current assets | 29/58 | €65k |
| Amounts receivable within one year | 40/41 | €10k |
| Investments | 50/53 | €56k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €71k |
| Equity | 10/15 | €10k |
| Contributions / capital | 10/11 | €1k |
| Accumulated profits (losses) | 14 | €9k |
| Amounts payable | 17/49 | €60k |
| Amounts payable within one year | 42/48 | €60k |
| Income statement | ||
| Gross operating margin | 9900 | €91k |
| Operating result | 9901 | €2k |
| Financial charges | 65 | €441 |
| Result before taxes | 9903 | €1k |
| Income taxes | 67/77 | €368 |
| Net result for the period | 9904 | €1k |
| Result to be appropriated | 9905 | €1k |
| NACE primary | Agriculture(01610) |
| Legal form | Limited partnership(612) |
| Incorporation | 20-01-2021 |
| Status | Active |
| Postal code | 1180 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21616A0190/00A002 | Brussels | 1,849 m² | 1 · 315 m² | 30.4 m · 9 fl. |
| 21616A0183/00B060 | Brussels | 901 m² | 1 · 463 m² | 21.8 m · 6 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
26-03-2025 Registered office moved within Uccle
- Avenue de l'Aulne 106 boite 10 à 1180 Uccle → Chaussée d'Alsemberg 733 boite 28 à 1180 Uccle
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "Chauss\u00E9e d\u0027Alsemberg 733 boite 28 \u00E0 1180 Uccle",
"city": "Uccle",
"region": "brussels_hoofdstedelijk_gewest",
"street": "Chauss\u00E9e d\u0027Alsemberg",
"country": "BE",
"postcode": "1180",
"box_number": "28",
"street_number": "733",
"locality_suffix": null
},
"old_address": {
"raw": "Avenue de l\u0027Aulne 106 boite 10 \u00E0 1180 Uccle",
"city": "Uccle",
"region": "brussels_hoofdstedelijk_gewest",
"street": "Avenue de l\u0027Aulne",
"country": "BE",
"postcode": "1180",
"box_number": "10",
"street_number": "106",
"locality_suffix": null
},
"effective_date": "2025-02-24",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide de transf\u00E9rer le si\u00E8ge social \u00E0 Chauss\u00E9e d\u0027Alsemberg 733 boite 28 \u00E0 1180 Uccle en date du 24/02/2025 par facilit\u00E9 de r\u00E9ception de courrier et de traitement du dossier chez le comptable.",
"region_changed": false,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "header_volledig_adres",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "immediate",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-03-26",
"filing_date": "2005-03-19",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"date": "2025-02-24",
"unanimous": null
},
"subject_company": {
"kbo": "0761.814.640",
"name_full": "GLOBAL BIODESIGN",
"legal_form": "Soci\u00E9t\u00E9 en commandite simple",
"_kbo_filled_from_list": true
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Macadar Angier Victor",
"org_rep_person_name": null,
"person_role_at_subject": "Administrateur"
},
"co_filed_documents": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | Global Biodesign |